Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• Dysport (abobotulinumtoxin A) is indicated for the treatment of cervical dystonia in adults, the temporary improvement in the appearance of moderate to severe glabellar lines associated with procerus and corrugator muscle activity in adults under 65 years of age, and the treatment of spasticity in patients 2 years of age and older.
• This summary is based on the review of eight systematic review(s)/meta-analysis(es). ^[1-8]
• Neurogenic Detrusor Overactivity (NDO): No statistically significant differences were identified between abobotulinumtoxinA (aboBoNT-A) and onabotulinumtoxinA (onaBoNT-A) in reducing weekly urinary incontinence episodes. However, abobotulinumtoxinA showed numerically better outcomes at all endpoints, with clinically relevant differences observed at 12 and 24 weeks when comparing aboBoNT-A 800U with onaBoNT-A 200U.
• Upper Facial Aesthetic Indications: Patient satisfaction with aesthetic results was consistently higher than placebo from two weeks up to 3-5 months post-injection, with satisfaction rates ranging from 52%-99% at 2-3 weeks, 85%-87% at 5 months, and 25%-100% at 6 months. There were no significant differences in satisfaction by sex or age.
• Cervical Dystonia (CD): Moderate to large improvements in clinical status were observed with an average 18.4% improvement from baseline on the Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS), accompanied by high satisfaction among both patients and clinicians.
• For Neurogenic Detrusor Overactivity (NDO), there were no statistically significant differences in the occurrence of treatment-emergent urinary tract infections (TE-UTIs) between abobotulinumtoxinA (aboBoNT-A) and onabotulinumtoxinA (onaBoNT-A).
• For Cosmetic Indications (Middle & Lower Face, Neck) and Hyperhidrosis, no serious adverse events were reported.
• For Upper Facial Aesthetic Indications, no specific adverse events were mentioned.
• For Cervical Dystonia (CD), there was an increased risk of adverse events with a relative risk of 1.23. Common adverse events included neck weakness (14%), dysphagia (11%), and diffuse weakness or tiredness (8%).
• For Pediatric Lower Limb Spasticity, adverse events were comparable across all doses of onabotulinumtoxinA.
• Specific Population Types and Subgroup Considerations: The reviewed evidence highlights specific populations for each indication: refractory Neurogenic Detrusor Overactivity (NDO) patients, adults under 65 for upper facial aesthetic indications, and children with lower limb spasticity. Notably, for upper facial aesthetic indications, patient satisfaction did not vary by sex or age. In pediatric lower limb spasticity, abobotulinumtoxinA showed significant or numerical efficacy advantages over onabotulinumtoxinA, with comparable tolerability.